ArticleMolecular biology reports2026
Evaluation of the antibacterial activity of Akkermansia muciniphila extract against Enterococcus faecium isolates.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emergence of multidrug-resistant Enterococcus faecium, particularly vancomycin-resistant strains (VRE), poses a significant global health threat and necessitates novel therapeutic strategies. Akkermansia muciniphila, a beneficial gut commensal, is a promising next-generation probiotic with antimicrobial properties. This study aimed to evaluate the antibacterial and antivirulence efficacy of A. muciniphila extract against clinical E. faecium isolates.
methodsSixty urine and fecal samples were collected from the Iraqi Hospital (October 2024 to February 2025). Fifteen clinical E. faecium isolates were confirmed by VITEK and 16 S rRNA sequencing. The presence of ace (adhesion) and esp (biofilm) virulence genes was determined using PCR. The antimicrobial activity of commercial A. muciniphila extract was assessed using agar well diffusion and broth microdilution to determine the Minimum Inhibitory Concentration (MIC). The effect of the extract on ace and esp gene expression was quantified by quantitative real-time PCR (qRT-PCR).
resultsAce and esp were detected in all 15 and esp in 13 strains, respectively. The A. muciniphila extract demonstrated significant growth inhibition, with an MIC of 6.25 mg/mL. Sub-inhibitory concentrations of the extract resulted in a significant downregulation of virulence gene expression, with ace expression reduced by up to 7.14-fold and esp expression reduced by up to 250-fold compared to the untreated controls (P < 0.05).
conclusionsA. muciniphila extract inhibited the growth of E. faecium and reduced the expression of virulence genes (ace/esp), suggesting potential therapeutic efficacy against drug-resistant infections. However, additional mechanistic studies and in vivo confirmation are required for clinical applications.
Indexed as
Identifiers
41579256What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.